High Potency APIs /HPAPI Market

Market Leader - High Potency APIs /HPAPI Market

The global HPAPIs market is expected to reach USD 26.84 Billion by 2023 from USD 17.72 Billion in 2018, at a CAGR 8.7%. The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies, and growing focus on precision medicine.

Agreements, partnerships, collaborations, and alliances accounted for the largest share of the overall growth strategies followed by key players between 2015 and 2018. Some of the key players in the HPAPIs market include Pfizer (US), Novartis (Switzerland), Merck (US), Teva (Israel), Mylan (US), Boehringer Ingelheim (Germany), Sanofi (France), F. Hoffmann-La Roche (Switzerland), AbbVie (US), Eli Lilly (US), Mylan (US), and Bristol-Myers Squibb (US).

Pfizer held the leading position in the HPAPIs market in 2017. The dominant position of the company can be attributed to its exhaustive product portfolio. The company has been operating in the APIs market for more than a decade and has a strong brand image, which gives it a competitive edge over other players. To remain competitive and strengthen its market position, the company primarily focuses on adopting both organic and inorganic growth strategies such as acquisitions and expansions. In 2015, Pfizer acquired Anacor Pharmaceuticals (US), a leading biopharmaceutical company and Hospira (US) a global leader in biosimilars. Such acquisitions enabled the company to expand its product offerings and global market presence.

Novartis International AG held the second position in the HPAPIs market. The company has a strong brand recognition among end users and a wide global presence. In order to maintain its leading market position, the company invests a significant amount of its revenue in R&D activities. In 2016, the company invested 18.6% of its total revenue (USD 9.0 billion) on R&D. This significant investment enables the company to launch innovative and technologically advanced products in the market. The company also focuses on inorganic growth strategies to strengthen its position in the market. For instance, in June 2016, Novartis entered into a licensing and collaboration agreement with Xencor (US), a biopharmaceutical company that develops engineered monoclonal antibodies. The purpose of this agreement was to develop bispecific antibodies for treating cancer. Such approaches help the company to strengthen its position in the global HPAPIs market.

Related Reports:

High Potency APIs /HPAPI Market by Type (Innovative, Generic), Synthesis (Synthetic, Biotech, moAB, Vaccines, Recombinant Proteins), Manufacturer (Captive and Merchant), Therapy (Oncology, Glaucoma, Hormonal Imbalance) - Global Forecasts to 2023

Contact:
Mr. Rohan
MarketsandMarkets™ INC. 
630 Dundee Road 
Suite 430 
Northbrook, IL 60062 
USA : 1-888-600-6441 
sales@marketsandmarkets.com

Report Code
PH 4897
RI Published ON
4/19/2018
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the High Potency APIs /HPAPI Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved